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Abstract
Background
Clostridium difficile is the leading cause of antibiotic-associated diarrhoea and pseudo
membranous colitis in the developed world. The aim of this study was to explore whether
Photodynamic Antimicrobial Chemotherapy (PACT) could be used as a novel approach to
treating C. difficile infections.
Methods
PACT utilises the ability of light-activated photosensitisers (PS) to produce reactive oxygen
species (ROS) such as free radical species and singlet oxygen, which are lethal to cells.
We screened thirteen PS against C. difficile planktonic cells, biofilm and germinating spores
in vitro, and cytotoxicity of effective compounds was tested on the colorectal adenocarci-
noma cell-line HT-29.
Results
Three PS were able to kill 99.9% of bacteria in both aerobic and anaerobic conditions, both
in the planktonic state and in a biofilm, after exposure to red laser light (0.2 J/cm2) without
harming model colon cells. The applicability of PACT to eradicate C. difficile germinative
spores indirectly was also shown, by first inducing germination with the bile salt taurocho-
late, followed by PACT.
Conclusion
This innovative and simple approach offers the prospect of a new antimicrobial therapy
using light to treat C. difficile infection of the colon.
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Introduction
The emergence of microbial resistance to most of the known classes of antibiotics has led to an
urgent need to identify new antimicrobial strategies [1–5].
Photodynamic antimicrobial chemotherapy (PACT) involves the combination of a light-
sensitive dye, known as a photosensitiser (PS), and locally applied visible light [6,7]. Upon illu-
mination of the PS at one or more wavelengths corresponding to the absorption peaks, the
excited molecule can react with a target (molecular oxygen or other targets within biological
systems) by electron transfer generating radical species (Type I mechanism). Alternatively, the
excitation energy can be transferred from the excited triplet of the PS to triplet dioxygen form-
ing a ground state PS and excited singlet oxygen (Type II mechanism) (Fig 1A). Accumulation
of such reactive species, both radical and singlet oxygen, leads to irreversible damage to the tar-
get cell.
At present, numerous PS have been developed for the targeting of localised infections and
drug-resistant bacteria [8] and no microbial resistance to PACT has been reported so far [9–
11]. Despite this, clinical applications are still relatively limited.
The aim of the current work is to evaluate PACT as a treatment for Clostridium difficile
infections. This Gram positive anaerobic bacterium is the main cause of nosocomial antibiotic‐
associated diarrhoea (15%–25% of cases) and is an increasingly common pathogen in the com-
munity [12] with a significant economic burden on the healthcare system. C. difficile infection
occurs following disequilibrium in the intestinal microbiota, usually caused by broad-spectrum
antimicrobial therapy, or as a result of compromised immunity [13]. Recurrence of symptoms,
as a consequence of relapse of the original infection, occurs in 5–47% of cases [14]. The main
virulence factors of this organism are the two toxins A and B, however other factors such as
sporulation, and antibiotic resistance are also likely to be important[15,16],. Symptoms range
in severity from mild to severe with possible serious implications like toxic megacolon (0.4%-
3% of the cases) [17–19]. Treatment usually involves the use of vancomycin and metronidazole
[17]. Research into new treatments has focused on the development of new antibiotics (i.e.
fidaxomicin, tigecycline or nitazoxanide) [17], faecal transplant [20], probiotics [18], monoclo-
nal antibodies against the toxins [21], toxoid vaccines [22,23] or treatment with non-toxigenic
strains [24].
The aim of the work presented was to screen and characterise different PS to select the most
effective option for the development of PACT against C. difficile cells, biofilm and germinative
spores.
Materials and Methods
Strains and growth conditions used in this study
C. difficile was routinely grown in Brain Heart Infusion (BHI) broth or agar (Oxoid) at 37°C in
an anaerobic (10% CO2, 10% H2, 80% N2) workstation (MACS-MG-1000, Don Whitley Scien-
tific). Biofilms were grown in BHI broth supplemented with 0.1% cysteine (BHIS). All experi-
ments were performed on strain R20291 (Anaerobe Reference Laboratory, Cardiff, UK) or
CD1457, CD1458, CD1481, CD1490 and CD1523 (Table 1).
PS used in this study
Methylene blue, talaporfin and chlorin e6 were purchased from Sigma-Aldrich, MedKoo and
Frontier Scientific via their UK distributor, Inochem Ltd, respectively. S2 and S4, sulfonated
aluminium phthalocyanines, were a generous donation from Professor David Phillips (Impe-
rial College London). PB021, PB031, PB065, PB066, and PB067 consist of various chemical
PACT for Clostridium difficile
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modifications around a central Pyropheophorbide-a (PPa) molecule carried out by chemists
led by Dr Gokhan Yahioglu (PhotoBiotics Ltd.) and Dr Ioanna Stamati (Imperial College Lon-
don) [25]. m-THPC was clinical grade material provided by Quanta Nova. TPC-SNT was
donated by Dr Sinan Battah, Organix Ltd. (University of Essex). The compound TPC-SNT is a
Fig 1. Mechanism of PACT (A) and post PACT live/dead viability assay onC. difficilewith light only
(B), and PB031 (C) staining alive (green) and dead (red) bacteria. Scale bars represent 10 μM.
doi:10.1371/journal.pone.0135039.g001
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sulfonated chlorin with beta substituted hydrazon functionality. All structures are shown in S1
Fig.
PB021, PB031, PB065, PB066 and PB067 were all characterised by 1H, 13C nuclear magnetic
resonance (NMR), liquid chromatography–mass spectrometry (LC-MS) and high-resolution
mass spectrometry (HRMS) with accurate mass determination and were all 98% pure. The
purity of S2 and S4 were determined to be 95% by reverse-phase high performance liquid
chromatography (HPLC) and characterised by mass spectrometry (MS) (FAB, negative ion
mode). mTHPC and TPC-SNT were characterised by NMR, HPLC and electrospray mass
spectrometry (ESMS). m-THPC was 98% and TPC-SNT 95% pure. All other PS were obtained
from commercial sources and were the best grade available.
Stock solutions of each PS (1 mM) were prepared in sterile phosphate buffer saline (PBS)
with the exception of PPa and its derivatives, which were diluted in DMSO. Solutions were
kept in the dark at -20°C for a maximum of two weeks before use.
UV-visible absorption spectra of the PS in DMSO or BHI broth were recorded using a
Lambda 25 UV/VIS spectrophotometer (Perkin Elmer). Log P and Log D values were predicted
computationally with MarvinSketch Freeware Version: 5.7.0 (ChemAxon Ltd. www.
chemaxon.com.)
PS were irradiated with the appropriate source of light after irradiance was calibrated using
a laser power meter (Gentec TPM-300).
Table 1. C. difficile clinical isolates kill following PACT (665nm, 0.24 J/cm2) performed with methylene blue, S4, chlorin e6 and talaporfin (100 μM);
< 1 log10 killing (−); 1 to < 3 log10 killing (+); 3 to 4 log10 killing (++); > 4 log10 killing (+++).
Strain Ribotype PS (100 uM) Light Dark
CD1457 173 Methylene blue ++ +
S4 +++ -
Chlorine e6 +++ +
Talaporﬁn ++ -
CD1458 011 Methylene blue ++ +
S4 +++ -
Chlorine e6 +++ +
Talapoﬁn ++ -
CD1481 249 Methylene blue +++ +
S4 +++ -
Chlorine e6 +++ -
Talaporﬁn ++ -
CD1490 027 Methylene blue +++ +
S4 +++ -
Chlorine e6 +++ +
Talaporﬁn ++ -
CD1523 020 Methylene blue +++ -
S4 ++ -
Chlorine e6 +++ -
Talaporﬁn +++ -
R20291 027 Methylene blue +++ +
S4 +++ -
Chlorine e6 +++ -
Talaporﬁn +++ -
doi:10.1371/journal.pone.0135039.t001
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In vitro sensitisation of C. difficile vegetative cells
C. difficile was grown with agitation (50 rpm) for 16 hours, typically reaching an optical density
(OD)600 of 1.0, corresponding to approximately 10
9 cfu/ml. The cultures were serially diluted
in BHI supplemented with the desired concentration of PS or with the PS solvents as control.
All dilutions were performed in duplicate and 20 μl of each dilution were spotted onto BHI
agar (1 ml contained in the wells of a 24 well tissue culture plate). Plates were set up in dupli-
cate with one plate exposed to light and the other kept in the dark. The plates were protected
from light except during the period of exposure to Periowave diode lasers (Ondine Biomedical
Inc., Canada). Light delivery was performed within five minutes of PS incubation unless other-
wise stated. Plates were returned to the anaerobic cabinet and incubated for 48 hours. Data
were collected by recording the presence of colonies. When the experiments were performed in
anaerobic conditions, all steps were carried out inside an anaerobic cabinet (MACS-MG-1000,
DonWhitley Scientific) and solutions were deaerated in the anaerobic cabinet for a minimum
of two hours before use. When PS cell binding or internalisation was to be evaluated, the bacte-
ria were recovered by centrifugation (1070 g, 5 minutes) and washed three times with 1 ml of
BHI broth to eliminate extracellular, unbound PS prior to diluting. The effect of PACT with
methylene blue, chlorin e6, PB031, S4 and talaporfin on C. difficile viability was recorded via
fluorescent microscopy (Olympus BXS1) using a LIVE/DEAD BacLight Bacterial Viability Kits
(Life technologies) according to the manufacturer’s instructions.
In vitro sensitisation of C. difficile germinative spores
To isolate C. difficile spores, strain R20291 was grown without shaking in BHI broth for four
days and vegetative cells were heat-killed at 65°C for 20 minutes. To determine their sensitivity
to PACT, spores were treated with the appropriate PS, with and without co-incubation with
0.1% sodium taurocholate for the desired amount of time, and 20 μl of 10-fold serial dilutions
were plated on to BHI agar containing 0.1% sodium taurocholate (1 ml in the wells of a 24 well
plate). Plates were returned to the anaerobic cabinet for the appropriate incubation time before
laser exposure and incubation as described.
In vitro sensitisation of C. difficile biofilm
C. difficile R20291 biofilm was prepared as described by Dawson et al. [26] with some modifi-
cations. Briefly, 1 ml of pre-reduced BHIS was inoculated with a 1 in 10 dilution of a 16 hour
culture of C. difficile R20291 into each well of a polystyrene 24-well tissue culture plate (BD Fal-
con). Medium only was added as a control. Biofilms were grown for six days before being
washed once with sterile distilled H2O (dH2O) and covered with 50 μl of a PS solution at the
appropriate final concentration. The same amount of dH2O was used as a control. Each experi-
ment was performed in the presence and absence of light and each treatment comprised two
technical replicates. After treatment, the bacteria were resuspended by vigorous pipetting in 1
ml of BHI broth, washed and serially diluted for viable counts on BHI agar plates which were
incubated for 48 hours in anaerobic conditions.
In vitro sensitisation of HT-29 cells
An adherent colorectal adenocarcinoma cell line (HT29) was plated at 30,000 cells per well in
black 96-well plates in 200 μl of the cell culture medium DMEM:F12 (Lonza) supplemented
with 10% Foetal Calf Serum (FCS) (Invitrogen) and 1% Penicillin-Streptomycin Solution
(Sigma-Aldrich). After 24 hours, the medium was replaced with PS solutions in PBS mixed 1:1
with supplemented cell culture medium. Controls comprised cells exposed to cell culture
PACT for Clostridium difficile
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medium:PBS (1:1) (100% viability), medium plus 0.25% Triton X100 (0% cell viability), and
medium alone without cells (background absorbance). Every condition was repeated across
four different wells (technical replicate n = 4). Plates were protected from light and incubated
in a humidified incubator (37°C/5% CO2) for 5 minutes or 2 hours. When required, extracellu-
lar unbound PS was removed by washing the adherent cells twice with PBS. Cells were then
either irradiated at 665nm delivering 0.24 J/cm2 over 10 seconds with a Periowave diode lasers
or left in the dark. After irradiation, cells were washed once with PBS and then returned to sup-
plemented cell culture medium. After a further 24 hours incubation, the medium was replaced
with MTS reagent (Promega) diluted 1:10 into 100 μl un-supplemented cell culture medium
and plates were returned to the incubator for 2 hours. Plates were gently shaken for 2 minutes
then the absorbance at 490 nm was measured on an ELx800 Absorbance Microplate reader
(BioTek).
Statistical analysis
All experiments were repeated at least three times and consisted of a minimum of two technical
replicates. The mean and standard error of the mean (SEM) were calculated and statistical sig-
nificance was analysed using a two-tailed, unpaired Student T-test.
Results
Absorption spectra and characterisation of PS
Absorption spectra were recorded in different solvents (Fig 2). All PS were soluble in DMSO
but not all were fully soluble in BHI. mTHPC in BHI formed a particulate and subsequent scat-
tering of the light was observed in the spectra. If exposed to centrifugal force this came out of
solution as a visible pellet. PB031, PB065, PB066 and PB067 all produced significant solid pre-
cipitation and the remaining PS were soluble (methylene blue, talaporfin, chlorin e6, S4, S2,
PPa, PB021, TPC-SNT).
Absorption peaks (in DMSO and BHI broth) of each PS are shown in Table 2 together with
the wavelength of the laser used and Log P and Log D values (indicating hydrophobicity of the
compounds in a non-ionised and ionised state respectively). The singlet oxygen quantum
yields, where available, were extrapolated from the literature or from the suppliers’ information
(Table 2).
PACT on cultures of C. difficile in the presence or absence of oxygen
Thirteen PS were tested for their ability to kill C. difficile in vitro. To date, most PACT mecha-
nisms of action have been shown to require molecular oxygen for bacterial targeting [6]. There-
fore, an initial screening was performed in which light was delivered in the presence of oxygen.
C. difficile killing was compared to an untreated control kept in the dark. Cells were treated
with 14 different PS at concentrations of 10 and 100 μM. Red or Near Infrared (NIR) laser light
was delivered at either 665, 652 or 784 nm and was matched to each PS depending on their
absorbance profile. Light was delivered at a relatively low dose for 10 seconds with light dose
between 0.24 and 0.71 J/cm2.
Red or NIR light alone did not show any reduction in viable bacteria. The results of C. diffi-
cile killing experiments are shown in Table 3. Methylene blue was the only PS to kill in the dark
(1 log10 reduction in bacterial numbers) but its effect was amplified by the delivery of red light
(> 4 log10 reduction in bacterial numbers) (Table 3). Bacterial kill was also visualised by Bac-
Light Live/Dead assay (Fig 1B and 1C).
PACT for Clostridium difficile
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PS showing a significant bactericidal effect, defined as3-log10-unit killing (99.9%) of the
initial inoculum (Clinical and Laboratory Standards Institute 1999) 25, 26 were selected for fur-
ther characterisation and the working concentration of 100 μMwas used throughout the study
to maximise the chance of future in vivo efficacy. The antimicrobial activity of the nine PS
(methylene blue, talaporfin, chlorin e6, S2, S4, PPa, PB031, PB065 and PB066) (Table 3) fulfill-
ing these criteria were also tested in the absence of oxygen to mimic the conditions found in
the colon, and four PS maintained their activity in these conditions (Table 3).
The four PS that were able to kill C. difficile in anaerobic conditions (talaporfin, S4, chlorin
e6 and PB031) were selected for further characterisation together with methylene blue, since it
is already approved for use in humans[27–29].
Blue light killing of C. difficile in the absence of PS
A 410 nm LED light delivery system (Enfis High-Power LED light engine) was also tested.
Many of the PS tested also had absorbance peaks in the blue range of the spectra and their bac-
tericidal activity was tested in conjunction with these wavelengths. However, blue light alone in
aerobic conditions was sufficient to kill C. difficile in the absence of PS. Different light doses
Fig 2. Absorbance spectra of PS in either DMSO (solid line) or BHI (dashed line), overlaid is the
relevant laser excitation wavelength in red at 665nm 652nm or 784nm. For spectra comparison, all PS
solutions were diluted to 50 μM concentration except Chlorin-e6, PPa and PB067 (25μM), S2 and S4
(6.7 μM), and PB066 (8.35 μM).
doi:10.1371/journal.pone.0135039.g002
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Table 2. Main characteristics of the PS used in this study.
Photosensitiser
(PS)
Abs Max (in
DMSO) nm
Abs Max
(in BHI)
nm
Laser
used
(nm)
Predicted Log P
(Non-ionic
species)
Predicted Log D
(Ionic species at
pH7.4)
Predicted
Ionisation at
pH7.4
Singlet Oxygen
Quantum Yield
(Solvent)Ref
Methylene Blue 670 670 665 2.61 2.61 1 0.50 (Ethanol)26
mTHPC 650 657 665 9.21 9.2 0 0.30 (Ethanol)26
Talaporﬁn 663 656 665 and
652
5.85 -6.55 -4 0.77 (Methanol)27
Chlorin-e6 663 656 665 7.02 -2.71 -3 0.61 (Toluene)26
S2 678 677 665 7.4 5.13 -1 0.27 (Methanol)28
S4 679 677 665 7.01 4.75 -1 0.20 (DMF)28
PPa 668 709 665 7.15 3.97 -1 0.50 (Toluene)29
PB021 673 687 665 9.34 6.04 -1 0.56 (Toluene)29
PB031 671 688 665 3.86 3.86 1 Not available
PB065 669 680 665 8.28 8.28 0 Not available
PB066 668 677 665 7.94 7.94 0 0.14 (Toluene)30
PB067 668 none 665 3.84 3.84 1 Not available
TPC-SNT none none 665 8.9 -0.61 -4 Not available
doi:10.1371/journal.pone.0135039.t002
Table 3. PACT inducedC. difficile kill (strain R20291) in aerobic (+O2) and anaerobic (-O2) conditions with light, no PS (L+ PS −); no light, no PS (L-
PS −); light and PS (L+ PS +); no light and PS (L- PS +). < 1 log10 killing (−); 1 to < 3 log10 killing (+); 3 to 4 log10 killing (++); > 4 log10 killing (+++).
PS L+ PS - L- PS - L- PS + L+ PS + (+O2) L
+ PS + (-O2) Energy (J/cm
2)
Methylene blue 100 - - + +++ + 0.24
10 - - + ++ 0.24
mTHPC 100 - - - - 0.24
10 - - - - 0.24
Talaporﬁn 100 - - - +++ +++ 1.4
10 - - - + 0.24
Chlorin e6 100 - - - +++ +++ 0.24
10 - - - +++ 0.24
S2 100 - - - ++ + 0.24
10 - - - - 0.24
S4 100 - - - +++ +++ 0.24
10 - - - +++ 0.24
PPa 100 - - - +++ - 0.24
10 - - - +++ 0.24
PB021 100 - - - - 0.24
10 - - - - 0.24
PB031 100 - - - +++ +++ 0.24
10 - - - +++ 0.24
PB065 100 - - - +++ - 0.24
10 - - - +++ 0.24
PB066 100 - - - +++ - 0.24
10 - - - +++ 0.24
PB067 100 - - - + 0.24
10 - - - - 0.24
TPC-SNT 100 - - - - 0.24
10 - - - - 0.24
doi:10.1371/journal.pone.0135039.t003
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were administered: 0.24 J/cm2 (0.018 W/cm2 for 13 seconds) resulted in a greater than 3 log10
reduction in bacterial numbers and 0.54 J/cm2 (0.018 W/cm2 for 30 seconds) resulted in a 4
log10 reduction (S2 Fig). Interestingly, these wavelengths did not show any antimicrobial activ-
ity against Enterococcus faecium, Pseudomonas aeruginosa or Escherichia coli excluding a gen-
eral antimicrobial mechanism (data not shown). Exposure of C. difficile to blue light in
anaerobic conditions did not cause any reduction in bacterial numbers (data not shown) and
delivery of blue light did not affect the viability of C. difficile spores (data not shown).
PS binding and internalisation in the target cell
PS (100 μM) were incubated with bacteria for 5 minutes or 2 hours before being removed by
washing with BHI broth prior to PACT. The level of bacterial killing after light delivery (665
nm, 0.24 J/cm2) was then compared with that of the unwashed bacteria. Table 4 shows that
chlorin e6 and PB031 retained full antimicrobial activity when incubated with the bacteria for
only five minutes prior to washing and light exposure. This suggests that these PS are rapidly
taken into the bacterial cytoplasm or are bound within the cell wall or to the cell surface. In
contrast, S4, methylene blue and talaporfin showed no antimicrobial activity even when incu-
bated with the bacteria for two hours prior to washing and light exposure, suggesting that they
are active from an extracellular location.
Cytotoxicity of PS to HT-29 colorectal cells
Cytotoxicity of PS (methylene blue, chlorin e6, PB031 and talaporfin) to mammalian cells was
evaluated in the colorectal adenocarcinoma cell line, HT-29. PS cytotoxicity was determined at
concentrations of 100 μM, 50 μM and 10 μM and red light was delivered for 10 seconds using a
laser emitting at 665 nm with energy of 0.24 J/cm2 (0.024W/cm2 for 10 seconds). The PS were
incubated with the HT-29 cells for 5 minutes or 2 hours and then irradiated. After 5 minutes,
none of the PS showed any cytotoxicity to the colonic cells, whereas after 2 hours, PB031 exhib-
ited a cytotoxic effect at 50 μM and above (Fig 3) and was therefore not characterised further.
PS removal by washing prior to laser exposure did not reduce the toxic effect of PB031 at these
concentrations (data not shown). S4 was also found to be non-cytotoxic but the experiment
was performed once with four technical repeats due to a limited supply of the PS (data not
shown). Light or PS alone did not impact on cell viability (data not shown).
In order to assess the maximum dose of light that could be administered without PS cyto-
toxicity, the light power was increased to up to 7.2 J/cm2 (0.024 W/cm2 for up to five minutes)
with a PS concentration of 50 μM. The results showed that methylene blue and talaporfin
remained non-toxic to HT29 cells whereas chlorin e6 became significantly cytotoxic at a light
power of 1.44 J/cm2 and S4 was toxic at 7.2 J/cm2 (S3 Fig).
Table 4. The effect of cell washing on PACT-mediated killing ofC. difficile (strain R20291) by different PS; < 1 log10 killing (-); > 4 log10 killing (+++)
PS Kill Kill Kill
5 min incubation 5 min incubation 2 hours incubation
no wash + wash + wash
Methylene blue +++ - -
Talaporﬁn +++ - -
Chlorin e6 +++ +++ +++
S4 +++ - -
PB031 +++ +++ +++
doi:10.1371/journal.pone.0135039.t004
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PACT on C. difficile clinical isolates belonging to different ribotypes are
equally susceptible to PACT
Five recent C. difficile clinical isolates belonging to different ribotypes were tested for suscepti-
bility to PACT using PS that were active against C. difficile R20291 but not cytotoxic to HT29
cells (methylene blue, S4, chlorin e6 and talaporfin) (Table 1). All the PS showed significant
bactericidal activity under the same light conditions that killed strain R20291, causing> 3
log10 reduction in bacterial numbers. Methylene blue and chlorin e6 showed limited bacteri-
cidal activity in the dark with three of the five strains (Table 1).
PACT treatment of C. difficile germinative spores
PACT was assessed for its ability to kill C. difficile spores in vitro. At concentrations of 100 μM
and light delivered at 0.24 J/cm2, none of the PS was able to reduce the numbers of C. difficile
spores. Increasing the concentration of methylene blue to 5 mM and the laser energy to
14.4 J/cm2 in 10 minutes also failed to reduce the numbers of C. difficile spores (data not
shown). Sodium taurocholate was used to induce germination of C. difficile spores prior to
PACT. Sodium taurocholate is a primary bile salt present in the biliary tract and intestines of
humans [30]. Treatment with this salt has been shown to be safe in humans[31–33]. A concen-
tration of 0.1% sodium taurocholate was used as it induced the highest rate of spore germina-
tion compared to other concentrations (0.001% 0.01% and 1%) (data not shown). Incubation
Fig 3. Colon cell survival. Percentage cell viability of cultured HT-29 cells 24 hours after a 5 or 120 minutes
incubation with four photosensitiser (PS) and light delivery (665nm, 0.24 J/cm2) compared to the untreated
control kept in the dark. Bars represent the mean of three biological repeats with error bars indicating SEM.
* p < .05.
doi:10.1371/journal.pone.0135039.g003
PACT for Clostridium difficile
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of spores in the presence of 0.1% germinant and 100 μM PS for a minimum of 20 to 40 minutes
followed by treatment with red light (665 nm, 0.24 J/cm2 in 10 seconds) resulted in significant
reductions in the numbers of C. difficile germinative spores (Fig 4A). Incubation of the spores
for the same amount of time with PS alone did not result in any reduction in spore numbers
(data not shown). Any combinational cytotoxity of PS and sodium taurocholate (0.01%, 0.1%
and 1%) was excluded by testing in HT-29 cells (data not shown).
PACT on C. difficile biofilm in vitro
A six-day-old biofilm of strain R20291 was exposed to the four PS; methylene blue, S4, chlorin
e6 and talaporfin, and irradiated. Cell adherence was quantified by crystal violet staining before
PACT, and was equal to an OD595 of 1.04 (± 0.15). Irradiation of the biofilm for 10 seconds
(energy delivered 0.24 J/cm2 in 10 seconds) showed that the biofilm was resistant to 100 μM PS
but susceptible to 1 mM, with a 2 to 3 log10 reduction in bacterial numbers (Fig 4B). Further
exposure to the laser for one minute using 1 mM PS did not show any further increase in bacte-
rial kill (Fig 4B). No reduction in bacterial numbers was apparent when the biofilm was
exposed to PS in the dark (data not shown).
Discussion
This work is the first study to assess the efficacy of PACT to treat C. difficile infections. Previous
work on the photodynamic targeting of this organism focused on the decontamination of
Fig 4. (A) PACT onC. difficile spores; viable count of germinatedC. difficile post PACT (100 μMPS,
665nm,) after different incubation times with 0.1% taurocholate. (B) Number of bacteria within aC.
difficile biofilm after PACT (100 μMor 1mMPS, 665nm, 0.24 or 1.4 J/cm2). Bars represent the mean of
three biological repeats and the error bars indicate SEM, * p < .05, ** p < .001.
doi:10.1371/journal.pone.0135039.g004
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hospital surfaces with the PS, toluidine blue and rose bengal [34] or blue light therapy [35],
with the latter showing activity against bacterial spores as well as vegetative cells.
In our work, nine PS out the 14 tested caused a reduction in bacterial numbers of more than
four log10 and four (chlorin e6, talaporfin, S4 and PB031) showed antimicrobial activity under
anaerobic conditions, making them particularly suitable for treatment of C. difficile within the
human colon. Therefore, these PS were investigated further alongside methylene blue, since
this molecule is already approved for clinical use [29] and could be more rapidly taken forward
for pilot clinical studies. Similarly, since 2004 talaporfin has been approved in Japan for lung
cancer treatment [36] and is currently in phase III clinical trials in the USA [37].
Although the exact mechanism of action of the PS is yet to be determined, we propose that
methylene blue, S4, and talaporfin might be bactericidal via an extra-cytoplasmic target since
washing of these PS resulted in loss of bactericidal activity. On the other hand, chlorin e6 and
PB031 retained their ability to kill C. difficile after washing, suggesting that these molecules are
taken up by the bacteria or are tightly bound within the cell wall or at the cell surface from
where they inflict damage. Similar conclusions were reached by Huang et al. [38] who demon-
strated that washed Staphylococcus aureus cells incubated with methylene blue survived after
light irradiation, whereas a conjugate between polyethylenimine and chlorin(e6) (PEI-ce6) was
still active after washing.
In our study, we have shown that internalisation of the PS is not necessary for PACT in C.
difficile. The photodynamic inactivation of both Gram-positive and Gram-negative bacteria via
the generation of extracellular ROS have been previously described [39,40] and shown to be
dependent on a sufficient PS per cell ratio [41]. However, cell surface binding or internalisation
is expected to be advantageous in the gut environment as it will result in higher PS concentra-
tions at the site of infection at the time of light delivery.
A major parameter contributing to successful PACT is the optimal excitation of PS with the
correct light wavelength. It should be noted that for some PS, the excitation wavelength did not
match exactly with their absorption peaks, and that some PS exhibited shifts in absorption
spectra upon dissolution in DMSO or BHI.
PB021, mTHPC, PB067 and TPC-SNT did not kill C. difficile significantly (less than 3 log10
kill) in BHI medium. The inactivity of TPC-SNT is explained by the fact that its absorption
spectra did not precisely correspond with the lasers used. The absorption spectra of PB021 in
DMSO corresponded with the excitation laser light but once dissolved in BHI, a shift away
from the laser wavelength is observed (see Fig 2). The parent molecule (PPa) also showed a
similar shift in absorbance but still had significant bactericidal effect. Examination of the struc-
ture of PB021 suggests it may be more capable of forming multimeric micelle structures via its
hydrophobic centre and hydrophilic PEG-like tail; this is supported by a prolonged retention
time in size exclusion chromatography (data not shown). As well as spectral shifts reducing
laser light absorption, a change in absorption spectra of a PS indicates that the energy levels
available for excitation and/or transition back to ground state could be altered and this can
directly compromise PACT. The inactivity of PB067 can be explained by its complete solid pre-
cipitation out of BHI solution producing negligible absorption spectra at any wavelength, and
the inactivity of mTHPC could be related to its production of a turbid suspension solution
upon dissolution in BHI, both these characteristics are reflected in their absorption spectra (see
Fig 2).
PB031, PB065, and PB066 are all related compounds and all showed significant bactericidal
effect. PB031, a version of this family of compounds with a constant positive charge, was
shown to be internalised by the bacteria or bound to the bacterial surface. All three PS also
showed some (but not complete) solid precipitation in BHI broth suggesting that in the test
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environment, sufficient amounts of the monomeric PS were present to achieve a bactericidal
result or the bacterial cells counteracted any solvation effects seen in BHI alone.
Five PS (talaporfin, methylene blue, chlorin e6, S2 and S4) were soluble in BHI and retained
their spectral characteristics better between solvents. These PS all showed 3 log10 oxygen-
dependent bacterial kill, and all showed some oxygen-independent bacterial kill. Talaporfin,
chlorin e6, and S4 maintained 3 log10 kill in anaerobic conditions. In an anaerobic environ-
ment, type I PACT mechanisms will dominate so PS that show significant bacterial kill in both
anaerobic and aerobic conditions are likely type I dominant and PS that show a drop in bacte-
rial kill in anaerobic conditions are likely Type II dominant. Although a single predominant
mechanism for PACT has been inferred for each PS, these mechanisms may in fact differ for
the same PS when evaluated under different environmental conditions [42,43]. Further photo-
physical or molecular experimentation would have to be carried out to determine the exact rea-
son for differences in PS suitability for C. difficile PACT.
Our leading PS were shown to be equally effective towards five additional recent C. difficile
clinical isolates of different ribotypes indicating that their efficacy is not limited to particular
genotypes.
Microorganisms are known to be able to colonise their host, forming a tri-dimensional
matrix composed of adherent bacteria embedded in exo-polymeric substances (EPS), known as
a biofilm. This structure can protect microbial cells from environmental stress and therapeutic
agents including PACT [44]. An in vitro C. difficile biofilm was recently described [26,45] and
the data presented here shows that a biofilm displays higher resistance to PACT compared to
planktonic cells. A 10-fold increase in the PS concentration (1mM) compared to that used
against planktonic cells, reduced C. difficile viability by approximately 2.5 to 3 log10. The need
for higher PS concentrations might be due to limited diffusion in the EPS matrix [46] and the
fact that a further increase in light energy did not increase the PS antibacterial effect suggests
that either a small portion of cells always remains protected when embedded in the matrix, or
that PS photobleaching may occur. Additionally, PACT-resistant spores are likely to be present
within the biofilm which can germinate after treatment. Repeated PACT or the addition of bio-
film disrupting agents would be required if the biofilm mode of growth is relevant to C. difficile
within the colon, together with the co-delivery of germinants.
Although some PS were previously shown to inactivate Bacillus spores [47–49] PACT was
not successful in reducing the number of C. difficile spores under the conditions shown to kill
vegetative cells, confirming their high resistance [50], and the induction of germination was
required to effect killing. This indicates that future studies aimed at the eradication of C. diffi-
cile spores from patients and/or contaminated surfaces should include taurocholate, its func-
tional groups or analogous molecules [51] to induce germination prior to PACT. Maclean et al.
[35] previously showed up to 4 log10 reduction in the numbers of Bacillus spp. and C. difficile
spores upon illumination with 405 nm blue light at a much higher dose of 1.73 kJ/cm2, making
it a promising method for environmental decontamination but not for the treatment of
disease.
The killing of C. difficile planktonic cells with blue light was also shown [35], but our studies
have now revealed that this is achievable at much lower light energies. Interestingly, blue light
has antimicrobial activity against a number of bacteria [52] by targeting endogenous metabo-
lites that can act as internal PS [53–55] and C. difficile is known to synthesise a number of por-
phyrin compounds which typically absorb in the blue region of the spectra. In agreement with
the work of Maclean et al. [56] on S. aureus, this mechanism is oxygen-dependent, and no kill-
ing was observed in anaerobic conditions (data not shown). Although blue light was non-toxic
to the HT-29 cell line (data not shown), its utility in treating C. difficile is questionable in vivo
due to the predicted lower penetration depth in the colonic folds compared to red light [57].
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The cancer cell line HT-29 was selected for evaluation as it is derived from human colorectal
epithelium, the microenvironment upon which C. difficile reside in humans from which they
cause pathogenicity. It is known that tumour cells are more sensitive than normal cells to the
effect of PS. Oseroff et al. [58] evaluated a panel of rhodamine and cyanine dyes in vitro and
found the most effective PS caused marked toxicity to human squamous, bladder and colon
carcinoma cells lines but was minimally toxic normal human keratinocytes or monkey kidney
epithelial cells under the same conditions. PS are also retained for longer periods in tumour
than normal cells in vivo, achieving selectivity and increased sensitivity via this mechanism
[59]. If PS evaluated were not toxic to HT-29 cells, it is inferred that it is unlikely that they
would be toxic to normal colorectal epithelium under the same conditions. Our cell toxicity
experiments showed that the PACT conditions that kill C. difficile in vitro do not affect the via-
bility of colonic cells in vitro, with the exception of PB031.
In summary, this work showed potential for PACT as a treatment for C. difficile induced
disease. Non-cytotoxic PS showed significant bactericidal activity against C. difficile in vitro in
both aerobic and anaerobic conditions making them good candidates for in vivo studies. The
characterised PS showed that antimicrobial activity can occur when PS are either internalised/
bound to the cell or located extracellularly, suggesting that specific targeting of the PS for
example, using antibodies or bacteriophage, might increase PACT efficiency further. Finally,
co-delivery of spore germinants allowed killing of C. difficile spores suggesting future strategies
of fighting recurrence of infections using natural or synthetic germinants in combination with
antimicrobial therapy.
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